Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Two-year real-world retrospective safety evaluation with onabotulinumtoxinA across multiple therapeutic indications: Findings from the SYNCHRONIZE study.
Journal: Toxicon : official journal of the International Society on Toxinology
Published: March 28, 2025
SYNCHRONIZE: Real-World Retrospective Safety Analysis of Patients Treated with OnabotulinumtoxinA for More than One Therapeutic Indication.
Journal: Toxins
Published: August 29, 2024
Safety and Real-World Dosing of OnabotulinumtoxinA for the Treatment of Adult Spasticity: Post Hoc Analysis of the Adult Spasticity International Registry Study.
Journal: American journal of physical medicine & rehabilitation
Published: January 11, 2024
Does treadmill training with Hybrid Assistive Limb (HAL) impact the quality of life? A first case series in the United States.
Journal: Disability and rehabilitation. Assistive technology
Published: July 26, 2018
Iron-Insensitive Quantitative Assessment of Subcortical Gray Matter Demyelination in Multiple Sclerosis Using the Macromolecular Proton Fraction.
Journal: AJNR. American journal of neuroradiology
Published: September 29, 2017
Safety, Tolerability, and Sensorimotor Effects of Extended-release Dalfampridine in Adults With Cerebral Palsy: A Pilot Study.
Journal: Clinical therapeutics
Published: July 15, 2016
The Effectiveness and Safety of Exoskeletons as Assistive and Rehabilitation Devices in the Treatment of Neurologic Gait Disorders in Patients with Spinal Cord Injury: A Systematic Review.
Journal: Global spine journal
Published: June 28, 2016
Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
Journal: Clinical therapeutics
Published: September 02, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026